Product Description: Naporafenib (LXH254) is a potent, selective, orally active, type II BRAF and CRAF inhibitor, with IC50 values of 0.072 and 0.21 nM against CRAF and BRAF, respectively[1][2].
Applications: Cancer-Kinase/protease
Formula: C25H25F3N4O4
References: [1]CAPONIGRO, Giordano, et al. THERAPEUTIC COMBINATIONS COMPRISING A RAF INHIBITOR AND A ERK INHIBITOR. WO 2018051306 A1 20180322/[2]Kelli-Ann Monaco, et al. LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors. Clin Cancer Res. 2021 Apr 1;27(7):2061-2073.
CAS Number: 1800398-38-2
Molecular Weight: 502.49
Compound Purity: 99.86
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Bcr-Abl;p38 MAPK;Raf